SR-9011

SR‑9011 is a synthetic small molecule that acts as an agonist of the nuclear receptors Rev-Erbα (NR1D1) and Rev-Erbβ (NR1D2). It was developed by Professor Thomas Burris at Scripps Research. By activating these nuclear receptors, which are key regulators of the circadian clock, SR‑9011 modulates circadian rhythm and metabolic processes. Preclinical studies have shown that it can influence metabolism, reduce fat storage, enhance muscle endurance, lower cholesterol levels, and affect immune responses. It has demonstrated selective lethality to cancer cells and oncogene-induced senescent cells while sparing normal cells or tissues. Its main research applications include studying circadian biology, metabolism-related disorders (such as obesity and type 2 diabetes), cardiovascular diseases, neuroinflammation, and cancer[1][2][3][4][5][6][8].

Other names

1379686-29-9CHEMBL1961797CHEMBL-1961797CHEMBL 1961797DB14014DB-14014DB 14014VYI79FLZ6WVYI-79FLZ6WVYI 79FLZ6WGTPL8900GTPL-8900GTPL 8900BDBM50366239BDBM-50366239BDBM 50366239CS-4668CS4668CS 4668SB19005SB-19005SB 19005NCGC00347956–01AK547296AK-547296AK 547296AS–55867HY–16988Q15410183Q-15410183Q 15410183